Selected research
Industry Research
Genetic Disorders Drug Industry Research Report 2026
Market perspective
The global Genetic Disorders Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Genetic Disorders Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Genetic Disorders Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Genetic Disorders Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Genetic Disorders Drug include Takeda, Sanofi, Pfizer, Amgen, Vertex, Sarepta, GW Pharmaceuticals and BioMarin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Genetic Disorders Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Genetic Disorders Drug Market by Company
Takeda
Sanofi
Pfizer
Amgen
Vertex
Sarepta
GW Pharmaceuticals
BioMarin
Genetic Disorders Drug Segment by Type
Duchenne Muscular Dystrophy (DMD)
Cystic Fibrosis (CF)
Lysosomal Storage Disease (LSD)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Genetic Disorders Drug Segment by Application
Clinic
Hospital
Genetic Disorders Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Disorders Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Genetic Disorders Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Disorders Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Genetic Disorders Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Genetic Disorders Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Genetic Disorders Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Duchenne Muscular Dystrophy (DMD)
- Cystic Fibrosis (CF)
- Lysosomal Storage Disease (LSD)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
Applications
- Clinic
- Hospital
Companies covered
- Takeda
- Sanofi
- Pfizer
- Amgen
- Vertex
- Sarepta
- GW Pharmaceuticals
- BioMarin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Genetic Disorders Drug Market Size (2021-2032)
- 2.2.2 Global Genetic Disorders Drug Sales (2021-2032)
- 2.2.3 Global Genetic Disorders Drug Market Average Price (2021-2032)
- 2.3 Genetic Disorders Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Duchenne Muscular Dystrophy (DMD)
- 2.3.3 Cystic Fibrosis (CF)
- 2.3.4 Lysosomal Storage Disease (LSD)
- 2.3.5 Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 2.4 Genetic Disorders Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Genetic Disorders Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Genetic Disorders Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Genetic Disorders Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Genetic Disorders Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Genetic Disorders Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Genetic Disorders Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Genetic Disorders Drug, Product Type & Application
- 3.8 Global Manufacturers of Genetic Disorders Drug, Established Date
- 3.9 Global Genetic Disorders Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Genetic Disorders Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Genetic Disorders Drug Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Genetic Disorders Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Genetic Disorders Drug Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Genetic Disorders Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Genetic Disorders Drug Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Amgen
- 4.4.1 Amgen Company Information
- 4.4.2 Amgen Business Overview
- 4.4.3 Amgen Genetic Disorders Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amgen Genetic Disorders Drug Product Portfolio
- 4.4.5 Amgen Recent Developments
- 4.5 Vertex
- 4.5.1 Vertex Company Information
- 4.5.2 Vertex Business Overview
- 4.5.3 Vertex Genetic Disorders Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Vertex Genetic Disorders Drug Product Portfolio
- 4.5.5 Vertex Recent Developments
- 4.6 Sarepta
- 4.6.1 Sarepta Company Information
- 4.6.2 Sarepta Business Overview
- 4.6.3 Sarepta Genetic Disorders Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sarepta Genetic Disorders Drug Product Portfolio
- 4.6.5 Sarepta Recent Developments
- 4.7 GW Pharmaceuticals
- 4.7.1 GW Pharmaceuticals Company Information
- 4.7.2 GW Pharmaceuticals Business Overview
- 4.7.3 GW Pharmaceuticals Genetic Disorders Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GW Pharmaceuticals Genetic Disorders Drug Product Portfolio
- 4.7.5 GW Pharmaceuticals Recent Developments
- 4.8 BioMarin
- 4.8.1 BioMarin Company Information
- 4.8.2 BioMarin Business Overview
- 4.8.3 BioMarin Genetic Disorders Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 BioMarin Genetic Disorders Drug Product Portfolio
- 4.8.5 BioMarin Recent Developments
5 Global Genetic Disorders Drug Market Scenario by Region
- 5.1 Global Genetic Disorders Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Genetic Disorders Drug Sales by Region: 2021-2032
- 5.2.1 Global Genetic Disorders Drug Sales by Region: 2021-2026
- 5.2.2 Global Genetic Disorders Drug Sales by Region: 2027-2032
- 5.3 Global Genetic Disorders Drug Revenue by Region: 2021-2032
- 5.3.1 Global Genetic Disorders Drug Revenue by Region: 2021-2026
- 5.3.2 Global Genetic Disorders Drug Revenue by Region: 2027-2032
- 5.4 North America Genetic Disorders Drug Market Facts & Figures by Country
- 5.4.1 North America Genetic Disorders Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Genetic Disorders Drug Sales by Country (2021-2032)
- 5.4.3 North America Genetic Disorders Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Genetic Disorders Drug Market Facts & Figures by Country
- 5.5.1 Europe Genetic Disorders Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Genetic Disorders Drug Sales by Country (2021-2032)
- 5.5.3 Europe Genetic Disorders Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Genetic Disorders Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Genetic Disorders Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Genetic Disorders Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Genetic Disorders Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Genetic Disorders Drug Market Facts & Figures by Country
- 5.7.1 South America Genetic Disorders Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Genetic Disorders Drug Sales by Country (2021-2032)
- 5.7.3 South America Genetic Disorders Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Genetic Disorders Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Genetic Disorders Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Genetic Disorders Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Genetic Disorders Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Genetic Disorders Drug Sales by Type (2021-2032)
- 6.1.1 Global Genetic Disorders Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Genetic Disorders Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Genetic Disorders Drug Revenue by Type (2021-2032)
- 6.2.1 Global Genetic Disorders Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Genetic Disorders Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Genetic Disorders Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Genetic Disorders Drug Sales by Application (2021-2032)
- 7.1.1 Global Genetic Disorders Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Genetic Disorders Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Genetic Disorders Drug Revenue by Application (2021-2032)
- 7.2.1 Global Genetic Disorders Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Genetic Disorders Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Genetic Disorders Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Genetic Disorders Drug Value Chain Analysis
- 8.1.1 Genetic Disorders Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Genetic Disorders Drug Production Mode & Process
- 8.2 Genetic Disorders Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Genetic Disorders Drug Distributors
- 8.2.3 Genetic Disorders Drug Customers
9 Global Genetic Disorders Drug Analyzing Market Dynamics
- 9.1 Genetic Disorders Drug Industry Trends
- 9.2 Genetic Disorders Drug Industry Drivers
- 9.3 Genetic Disorders Drug Industry Opportunities and Challenges
- 9.4 Genetic Disorders Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst